<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">71137</article-id><article-id pub-id-type="doi">10.7554/eLife.71137</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>Functional CDKN2A assay identifies frequent deleterious alleles misclassified as variants of uncertain significance</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-243518"><name><surname>Kimura</surname><given-names>Hirokazu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-5"/><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-243519"><name><surname>Paranal</surname><given-names>Raymond M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-263996"><name><surname>Nanda</surname><given-names>Neha</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-243520"><name><surname>Wood</surname><given-names>Laura D</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-243521"><name><surname>Eshleman</surname><given-names>James R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-35604"><name><surname>Hruban</surname><given-names>Ralph H</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-95645"><name><surname>Goggins</surname><given-names>Michael G</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-243522"><name><surname>Klein</surname><given-names>Alison P</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-222900"><name><surname>Roberts</surname><given-names>Nicholas Jason</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8709-0664</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-7"/><xref ref-type="other" rid="par-8"/><xref ref-type="other" rid="par-9"/><xref ref-type="other" rid="par-10"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Department of Pathology</institution>, <institution>Johns Hopkins University</institution>, <addr-line><named-content content-type="city">Baltimore</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution>The Johns Hopkins University</institution>, <addr-line><named-content content-type="city">Baltimore</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-45030"><name><surname>Lou</surname><given-names>Emil</given-names></name><role>Reviewing editor</role><aff><institution>University of Minnesota</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>nrobert8@jhmi.edu</email> (NR);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>10</day><month>01</month><year>2022</year></pub-date><volume>11</volume><elocation-id>e71137</elocation-id><history><date date-type="received"><day>09</day><month>06</month><year>2021</year></date><date date-type="accepted"><day>06</day><month>01</month><year>2022</year></date></history><permissions><copyright-statement>Â© 2022, Kimura et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Kimura et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-71137-v1.pdf"/><abstract><p>Pathogenic germline <italic>CDKN2A</italic> variants are associated with an increased risk of pancreatic ductal adenocarcinoma (PDAC). <italic>CDKN2A</italic> variants of uncertain significance (VUSs) are reported in up to 4.3% of patients with PDAC and result in significant uncertainty for patients and their family members as an unknown fraction are functionally deleterious, and therefore, likely pathogenic. Functional characterization of <italic>CDKN2A</italic> VUSs is needed to reclassify variants and inform clinical management. 29 germline <italic>CDKN2A</italic> VUSs previously reported in patients with PDAC or in ClinVar were evaluated using a validated <italic>in vitro</italic> cell proliferation assay. 12 of the 29 <italic>CDKN2A</italic> VUSs were functionally deleterious (11 VUSs) or potentially functionally deleterious (1 VUS) and were reclassified as likely pathogenic variants. Thus, over 40% of <italic>CDKN2A</italic> VUSs identified in patients with PDAC are functionally deleterious and likely pathogenic. When incorporating VUSs found to be functionally deleterious, and reclassified as likely pathogenic, the prevalence of pathogenic/likely pathogenic <italic>CDKN2A</italic> in patients with PDAC reported in the published literature is increased to up to 4.1% of patients, depending on family history. Therefore, <italic>CDKN2A</italic> VUSs may play a significant, unappreciated role in risk of pancreatic cancer. These findings have significant implications for the counselling and care of patients and their relatives.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution>The Sol Goldman Pancreatic Cancer Research Center</institution></institution-wrap></funding-source><award-id>Pilot Grant</award-id><principal-award-recipient><name><surname>Roberts</surname><given-names>Nicholas Jason</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>S10 OD026859</award-id><principal-award-recipient><name><surname>Roberts</surname><given-names>Nicholas Jason</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution>The Rolfe Pancreatic Cancer Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Roberts</surname><given-names>Nicholas Jason</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>P50 CA622924</award-id><principal-award-recipient><name><surname>Klein</surname><given-names>Alison P</given-names></name><name><surname>Roberts</surname><given-names>Nicholas Jason</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution>The Japanese Society of Gastroenterology</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Kimura</surname><given-names>Hirokazu</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution>The Japan Society for Promotion of Science</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Kimura</surname><given-names>Hirokazu</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution>The Joseph C Monastra Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Roberts</surname><given-names>Nicholas Jason</given-names></name></principal-award-recipient></award-group><award-group id="par-8"><funding-source><institution-wrap><institution>The Geral O Mann Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Roberts</surname><given-names>Nicholas Jason</given-names></name></principal-award-recipient></award-group><award-group id="par-9"><funding-source><institution-wrap><institution>Art Creates Cures Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Roberts</surname><given-names>Nicholas Jason</given-names></name></principal-award-recipient></award-group><award-group id="par-10"><funding-source><institution-wrap><institution>Susan Wojcicki and Denis Troper</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Roberts</surname><given-names>Nicholas Jason</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Ralph H Hruban, has the right to receive royalty payments from Thrive Earlier Diagnosis for the GNAS in pancreatic cysts invention in a relationship overseen by Johns Hopkins University..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript, supporting files, and as Source data and Source code.</p></sec><supplementary-material><ext-link xlink:href="elife-71137-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>